Z-FLD

Molecule in development

A need for more specific diagnostic tools for detecting, characterizing and staging lymphoma

Lymphoma is a cancer of the lymphatic system which can occur at any age, but it is one of the most common causes of cancer for children and young adults, between 15 and 24 years old.

Blood test and biopsies are used to detect the presence of lymphoma and characterize their Hodgkin / Non Hodgkin nature. Fluorodeoxyglucose imaging is used for re-staging of lymphomas and assessment of residual disease as well as for re-staging of patients following a therapy but it has a low specificity as it shows the same sensibility for residual diseases and inflammation. Thus it has a low positive predictive value.

74200

estimated new cases of Non Hodgkin lymphoma in the US in 2019

19970

estimated deaths of patients with Non Hodgkin lymphoma in the US in 2019

Source:
National Cancer Institute

Z-FLD, molecule in development for onco-hematology

18F-FLUDARABINE

Z-FLD for lymphoma imaging (CHU Caen / Cyceron)

Z-FLD is an in-vivo biomarker drug candidate with a high specificity and high positive predictive value, demonstrated for indolent lymphoma.

This radiotracer may allow a better visualization of the tumor cells in lympho-proliferative diseases.

A phase I study (NCT 021 28 945) has led to a proof of concept of the molecule for humans. A phase III multi-centric clinical study will follow the license agreement signed with the French Alternative Energies and Atomic Energy Commission, which is the prerequisite before marketing authorization request in Europe and in the United States.

Z-FLD shows a high potential in molecular imaging for the evaluation of malignant blood disorders, especially lymphomas. This radiopharmaceutical may allow physicians to visualize lymphoid tumor cells where other current diagnostic techniques are limited in terms of specificity and sensitivity, avoiding interpretation difficulties encountered with current imaging methods for lymphomas.

Z-FLD’s higher specificity on the tumor tissue and low affinity for peripheral inflammatory tissue may allow physicians to visualize the tumor issue with a higher contrast, reducing the false positive risk.

For investigational use only – for more information, please contact medicalaffairs@zionexa.com

PRESS RELEASE
Fludarabine labelled with fluor 18: a new radiotracer for onco-hematology
VIEW PRESS RELEASE

Next generation in-vivo biomarkers

Find out more about what’s coming in in-vivo biomarkers for molecular imaging